Nuformix plc (LON:NFX – Get Free Report) shares fell 2.6% on Tuesday . The company traded as low as GBX 0.13 and last traded at GBX 0.15. Approximately 2,990,761 shares were traded during mid-day trading, a decline of 90% from the average session volume of 29,624,281 shares. The stock had previously closed at GBX 0.15.
Nuformix Stock Down 2.6%
The firm has a market capitalization of £3.86 million, a P/E ratio of -5.05 and a beta of 1.52. The firm’s 50-day simple moving average is GBX 0.17 and its 200-day simple moving average is GBX 0.19.
Nuformix (LON:NFX – Get Free Report) last issued its quarterly earnings results on Thursday, May 28th. The company reported GBX (0.02) EPS for the quarter.
About Nuformix
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.
Further Reading
- Five stocks we like better than Nuformix
- The AI Boom Is Turning This Cable Maker Into a Stock to Watch
- A Star Investor Just Trimmed Amazon—Here’s What It means
- Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look
- Home Depot Analysts See a Path to $375 and Beyond
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
